Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AVXL Anavex Life Sciences Corporation

-0.09 (-1.70%)
Feb 29 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 1,003,136
Bid Price 5.16
Ask Price 5.22
News -
Day High 5.5076


52 Week Range


Day Low 5.115
Company Name Stock Ticker Symbol Market Type
Anavex Life Sciences Corporation AVXL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.09 -1.70% 5.21 19:36:52
Open Price Low Price High Price Close Price Prev Close
5.43 5.115 5.5076 5.14 5.30
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,353 1,003,136 $ 5.28 $ 5,296,613 - 4.795 - 10.45
Last Trade Time Type Quantity Stock Price Currency
19:37:12 8 $ 5.22 USD

Anavex Life Sciences Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
422.06M 82.11M - 0 -47.51M -0.58 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Anavex Life Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No AVXL Message Board. Create One! See More Posts on AVXL Message Board See More Message Board Posts

Historical AVXL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.075.50764.7955.081,495,5030.142.76%
1 Month6.006.154.7955.471,249,367-0.79-13.17%
3 Months8.0210.454.7956.801,494,908-2.81-35.04%
6 Months7.9110.454.7956.731,212,630-2.70-34.13%
1 Year9.6810.454.7957.581,083,550-4.47-46.18%
3 Years13.0631.504.79512.701,284,345-7.85-60.11%
5 Years2.2131.502.1010.741,210,3763.00135.75%

Anavex Life Sciences Description

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2.

Your Recent History

Delayed Upgrade Clock